Heron Therapeutics (HRTX) Asset Writedowns and Impairment (2019 - 2024)
Heron Therapeutics (HRTX) reported Asset Writedowns and Impairment of $828000.0 for Q3 2024, up 437.66% on a YoY basis from $154000.0 in Q4 2023, and down 74.69% quarter-over-quarter from $3.3 million in Q2 2024.
Heron Therapeutics (HRTX) Asset Writedowns and Impairment (2019 - 2024) Analysis & Trends
Heron Therapeutics has reported Asset Writedowns and Impairment for 6 years, with the latest figure at $828000.0 in Q3 2024.
- For the quarter ending Q3 2024, Asset Writedowns and Impairment rose 437.66% year-over-year to $828000.0; the trailing twelve-month figure through Sep 2024 stood at $4.4 million (up 716.05% YoY), and the FY2023 full-year result was $617000.0, up 195.22% from the prior year.
- Asset Writedowns and Impairment for Q3 2024 stood at $828000.0, down from $3.3 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $3.3 million in Q2 2024, with the low at $8000.0 in Q3 2020.
- Historically, Asset Writedowns and Impairment has averaged $337894.7 across 5 years, with a median of $124000.0 in 2021.
- Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment surged 2811.11% — and 2021, when it slumped 84.22%.
- Heron Therapeutics' Asset Writedowns and Impairment stood at $786000.0 in 2020, then tumbled by 84.22% to $124000.0 in 2021, then sank by 36.29% to $79000.0 in 2022, then surged by 94.94% to $154000.0 in 2023, then soared by 437.66% to $828000.0 in 2024.
- The last three Asset Writedowns and Impairment figures came in at $828000.0 (Q3 2024), $3.3 million (Q2 2024), and $170000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Heron Therapeutics | 77.43 Mn | 47.47 Mn | 24.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 828,000.00 |
| Sep 30, 2024 | 828,000.00 |
| Jun 30, 2024 | 3.27 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 170,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Jun 30, 2023 | 155,000.00 |
| Jun 30, 2023 | 155,000.00 |
| Mar 31, 2023 | 154,000.00 |
| Mar 31, 2023 | 154,000.00 |
| Dec 31, 2022 | 79,000.00 |
| Dec 31, 2022 | 79,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 41,000.00 |